$ABEO News

HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

Abeona Therapeutics Inc. (ABEO) Q1 2026 Earnings Call Transcript

Abeona Therapeutics Q1 2026 Earnings Call: Complete Transcript

Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network

Abeona Therapeutics Q1 EPS $(0.30) Beats $(0.35) Estimate, Sales $8.720M Beat $4.572M Estimate

Abeona Therapeutics Activates Children's Hospital Of Philadelphia As Sixth Qualified Treatment Center To Treat ZEVASKYN Gene-Modified Cellular Sheets

HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

Abeona Therapeutics: Early Zevaskyn Revenue Marks A Key Inflection Point

Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript

Abeona Therapeutics (NASDAQ:ABEO) Reports First Commercial Revenue and Bolstered Balance Sheet in 2025

Abeona Therapeutics Q4 EPS $(0.34) Beats $(0.36) Estimate, Sales $5.420M Beat $5.270M Estimate

HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas

Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy

Abeona Therapeutics Announces First Commercial Patient Treatment With FDA-Approved ZEVASKYN Gene Therapy For RDEB Wounds At Lucile Packard Children's Hospital Stanford

Epidermolysis Bullosa Market Research Report 2025-2035: Abeona, Castle Creek, RHEACELL, and Chiesi Lead Innovations as Gene Therapies and Advanced Wound Care Accelerate Growth

Abeona Therapeutics (ABEO) Is Up 17.9% After Reporting Narrowed Losses and ZEVASKYN J-code Approval

Abeona Therapeutics Inc (ABEO) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ...